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The AMAZES study was a large randomised, double-
blind, placebo-controlled trial of azithromycin 
500 mg given three times a week for 48 weeks 
in adults with persistent uncontrolled asthma to 
decrease asthma exacerbations and improve asthma-
related quality of life [1]. The study was nationally 
funded in Australia and included 420 patients around 
the age of 60 years who were predominantly female 
(61%). Azithromycin reduced moderate-to-severe 
asthma exacerbations compared with placebo and 
significantly improved asthma-related quality of 
life. Only diarrhoea was significantly more frequent 
in users of azithromycin compared with placebo, 
although patients with hearing impairment or an 
abnormal prolongation of the corrected QT interval 
were excluded from the start of the study.
The patients with asthma included in the study 
were persistently symptomatic despite optimised 
asthma treatment with inhaled corticosteroids and 
long-acting bronchodilators. Importantly, since 
azithromycin showed no benefit in current smokers 
with chronic obstructive pulmonary disease [2], the 
patients with asthma included in the study were 
nonsmokers (confirmed by exhaled carbon monoxide 
<10 ppm) or ex-smokers with either ≤10 pack-years 
of smoking or without emphysema (confirmed by a 
carbon monoxide transfer coefficient ≥70% of the 
predicted value) [1]. Several measures were taken 
to favourably influence therapy adherence during 
the study. Only patients who were adherent (>80%) 
during a 2-week run-in period were randomised. 
Adherence was assessed during several study visits 
and telephone assessments were performed three 
times between study visits.
The primary aim was to evaluate the effect of 
azithromycin on asthma exacerbations. Therefore, 
the study sample was sized to take into account 
a baseline incidence of asthma exacerbations 
of 0.58 per person-year and a 35% reduction in 
exacerbation incidence by azithromycin. Moderate 
exacerbations were defined as worsening of asthma 
symptoms that led to any temporary increase in 
use of inhaled corticosteroids or antibiotics, or an 
increase in β2-agonist use for at least 2 days, or 
an emergency department visit (without systemic 
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corticosteroids). Severe exacerbations were defined 
as worsening of asthma symptoms that led to a 
10 mg·day−1 (increased) systemic corticosteroid 
treatment for at least 3 days or an asthma-specific 
hospitalisation or emergency department visit 
requiring systemic corticosteroids. Exacerbations 
were registered using patient daily diaries and 
structured interviews during the study centre visits. 
The study observed that azithromycin reduced the 
incidence of exacerbations by 41%.
The AMAZES study confirmed the previously 
observed benefit of macrolides on asthma symptoms 
and clearly contributed to the evidence for an effect 
on asthma exacerbations. However, potential 
phenotype-specific effects have not yet been 
fully clarified. The allergic eosinophilic phenotype 
is usually very corticosteroid sensitive, while the 
non-eosinophilic phenotype could especially 
benefit from therapies other than corticosteroids 
to control the innate immune dysfunction. While 
in the AZISAST study azithromycin decreased 
the exacerbation rate only in patients with non-
eosinophilic asthma [3], azithromycin reduced 
exacerbations in both eosinophilic asthma and non-
eosinophilic asthma within the AMAZES study [1]. 
However, the AMAZES study substantially differed 
from the AZISAST study in terms of phenotype 
definition, patient selection, duration and dosing 
of azithromycin. Even the primary outcome differed 
as the AZISAST study evaluated the effect on severe 
asthma exacerbations as well as on lower respiratory 
infections [1, 3]. In addition, sputum neutrophils 
did not differ between treatment groups within the 
AMAZES study [1].
Although macrolides are antibacterial (inhibiting 
bacterial protein biosynthesis) and potentially anti-
inflammatory (inhibiting eosinophil differentiation 
and accumulation of neutrophils, lymphocytes and 
macrophages), the AMAZES study also suggested 
pleiotropic antiviral effects since the benefit 
of azithromycin was observed on both asthma 
exacerbations and respiratory infections. Within 
the AMAZES study, azithromycin also affected 
lower respiratory tract infections in non-eosinophilic 
patients.
The clinical implication for asthma management 
is that azithromycin may offer relief as an add-on 
treatment in adult patients with persistent 
uncontrolled asthma during periods of increased 
exacerbations or respiratory infections. Before 
considering any additional therapy, avoidable 
exposures, treatable comorbidities, inhalation 
technique and therapy adherence to inhaled 
corticosteroids and long-acting β2-agonists 
should be evaluated first. Additional evidence 
would help clinical practice to tailor macrolides in 
uncontrolled asthmatics better or to support their 
cost-effectiveness.
While potentially preventing substantial costs 
by postponing use of monoclonal antibodies 
and reducing side-effects of maintenance oral 
corticosteroids, amazing life-saving antimicrobial 
agents also have drawbacks. One third of the 
patients on azithromycin treatment within the 
AMAZES study suffered from diarrhoea, which 
was significantly higher compared with placebo. 
Although the sputum cultures detecting potentially 
pathogenic microorganisms only increased slightly 
from 19.6% to 20.6% at the end of treatment 
among both groups, the long-term effects of real-
life use of maintenance macrolides on community 
microbial resistance requires further investigation. 
The risk–benefit assessment is undoubtedly 
different under real-life circumstances where 
cardiac risk assessment and therapy adherence will 
be less optimal, and therefore the observed benefits 
might be less amazing than observed within this 
randomised clinical trial.
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